石藥(01093.HK)終止與君實(01877.HK)之產品合作開發及戰略合作協議
石藥集團(01093.HK)公布,就治療乳腺癌的聯合用藥之臨床開發、註冊及商業化訂立戰略合作協議一事,為了避免與集團另一抗PD-1單克隆抗體在研藥物的臨床研究及未來商業化可能引起的潛在衝突,經雙方同意,公司與君實生物(01877.HK)於今年12月30日訂立終止該協議的協議。
根據終止協議,訂約雙方同意,任何一方不得向另一方就公司已向君實支付的3,000萬元人民幣(下同)之里程碑款項及君實已向集團支付的368.39萬元之臨床研究費用提出任何申索。公司亦無責任向君實支付任何進一步里程碑款項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.